

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM805533

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Finch Research and Development LLC		04/21/2023	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Finch Therapeutics, Inc.		
Street Address:	200 Inner Belt Road, Suite 400		
City:	Somerville		
State/Country:	MASSACHUSETTS		
Postal Code:	02143		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	5711767	FULL-SPECTRUM MICROBIOTA	
Registration Number:	5687748	RATIONALLY-SELECTED MICROBIOTA	
Registration Number:	5581205	FSM	
Registration Number:	5562837	FULL-SPECTRUM MICROBIOTA	
CORRESPONDENCE DATA			
Fax Number:	6173417701		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6179518961		
Email:	jennifer.kagan@morganlewis.com		
Correspondent Name:	Jennifer Kagan, Paralegal		
Address Line 1:	One Federal Street		
Address Line 2:	Morgan, Lewis & Bockius LLP		
Address Line 4:	Boston, MASSACHUSETTS 02110		
ATTORNEY DOCKET NUMBER:	112933-0009		
NAME OF SUBMITTER:	Jennifer Kagan, Paralegal		
SIGNATURE:	/Jennifer Kagan/		
DATE SIGNED:	04/24/2023		
Total Attachments: 3			

CH \$115.00 5711767

source=Trademark Assignment Finch Therapeutics.docx#page1.tif

source=Trademark Assignment Finch Therapeutics.docx#page2.tif

source=Trademark Assignment Finch Therapeutics.docx#page3.tif

TRADEMARK ASSIGNMENT

This TRADEMARK ASSIGNMENT (“Assignment”), effective as of the date of signature (the “Effective Date”), is by and between Finch Research and Development LLC, a limited liability company of Delaware (“Assignor”), and Finch Therapeutics, Inc., a corporation of Delaware, having a principal place of business at 200 Inner Belt Road, Suite 400, Somerville, Massachusetts 02143 (“Assignee”).

WHEREAS, Assignor is the owner of all right, title, and interest in and to the trademarks listed on the attached Schedule (the “Marks”); and

WHEREAS, Assignor desires to assign to Assignee, and Assignee desires to acquire from Assignor, all right, title and interest in and to the Marks, including all registrations therefor and goodwill related thereto.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:


1. Assignor represents and warrants that it is the sole owner of the Marks and has the authority to make this Assignment.

2. Effective as of the Effective Date, Assignor hereby assigns to Assignee all of its rights, title and interest in and to the Marks, including all common law rights in the Marks, the trademark registrations for the Marks, and all goodwill associated with the Marks. This Assignment includes the right to sue for and to recover damages for past, present and future infringements in any court and to bring any proceeding in the United States Patent and Trademark Office or any equivalent agency in any other country for cancellation or opposition or other proceeding based on or in connection with the Marks. This Assignment also includes the right of Assignee to record this Assignment with the United States Patent and Trademark Office. The right, title and interest in the Marks is to be held and enjoyed by Assignee and Assignee’s successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made.

3. This Assignment shall inure to the benefit of and be binding upon the Parties hereto and their respective successors and permitted assigns.

Dated: April 21, 2023

ASSIGNOR: Finch Research and Development LLC


By:  DocuSigned by:
B0EBE738B514442...

Name: Mark Smith

Title: CEO

ASSIGNEE: Finch Therapeutics, Inc.

Dated: April 21, 2023

By:  DocuSigned by:
B0EBE738B514442...

Name: Mark Smith

Title: CEO

Schedule

Mark	Registration No.
FULL-SPECTRUM MICROBIOTA	5711767
RATIONALLY-SELECTED MICROBIOTA	5687748
FSM	5581205
FULL-SPECTRUM MICROBIOTA	5562837